Wire · opportunities
Amgen submits new data to challenge FDA's proposal to withdraw Tavneos
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 July 2026 · Fusion42 review
Amgen submitted new evidence to the FDA on 23 July challenging the agency's proposed withdrawal of Tavneos, a rare-disease drug, citing over 70 real-world studies involving 2,200+ patients supporting its effectiveness and safety. The FDA proposed withdrawal in April citing lack of proven effectiveness and false statements in the original application, though the drug remains on the US market pending FDA commissioner action or Amgen's voluntary removal.
This Wire brief sits within Fusion42's coverage of Digital Health, and 2 sources have reported it between 24 Jul 2026 and 25 Jul 2026.
◆ ◆ The Wire takeaway
If you're building real-world evidence infrastructure or post-approval data platforms for rare disease drugs, the FDA's bar for 'effectiveness' just got much higher—Amgen is fighting withdrawal with 70 studies and 2,200 patients, and that may still not be enough. This is now table stakes for any rare-disease pharma: expect regulators to demand continuous proof of efficacy long after launch.
◆ Coverage
2 sources · first reported 24 Jul 2026 · latest 25 Jul 2026
◆ Related on Wire
◆ Topics